H.C. Wainwright analyst Brandon Folkes views the selloff in shares of MannKind (MNKD) post the Q2 report as overdone. The market “continues to miss” the drivers of MannKind’s future, which include Afrezza pediatric uptake and the pipeline of MNKD-101 and MNKD-201, the analyst tells investors in a research note. The firm believes the Q2 updates on MannKind’s future value drivers were largely positive. H.C. Wainwright believes the stock remains undervalued fundamentally. It keeps a Buy rating on MannKind with a $9 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind reports Q2 non-GAAP EPS 5c, consensus 8c
- MannKind, Blackstone enter up to $500M strategic financing agreement
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation’s Global Supply Chain Risks: Navigating Trade Policies and Financial Challenges
- MannKind’s Growth Potential Bolstered by United Therapeutics Partnership and Promising Pipeline